ATE300302T1 - Pharmazeutische zusammensetzung enthaltend einen metabolit von buspirone - Google Patents

Pharmazeutische zusammensetzung enthaltend einen metabolit von buspirone

Info

Publication number
ATE300302T1
ATE300302T1 AT00973636T AT00973636T ATE300302T1 AT E300302 T1 ATE300302 T1 AT E300302T1 AT 00973636 T AT00973636 T AT 00973636T AT 00973636 T AT00973636 T AT 00973636T AT E300302 T1 ATE300302 T1 AT E300302T1
Authority
AT
Austria
Prior art keywords
buspirone
metabolite
pharmaceutical composition
composition containing
pharmaceutical
Prior art date
Application number
AT00973636T
Other languages
English (en)
Inventor
Robert F Mayol
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27047894&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE300302(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE300302T1 publication Critical patent/ATE300302T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00973636T 2000-01-18 2000-10-18 Pharmazeutische zusammensetzung enthaltend einen metabolit von buspirone ATE300302T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48416100A 2000-01-18 2000-01-18
US09/588,221 US6150365A (en) 1999-08-05 2000-06-06 Anxiety method
PCT/US2000/028800 WO2001052853A1 (en) 2000-01-18 2000-10-18 Anxiety method

Publications (1)

Publication Number Publication Date
ATE300302T1 true ATE300302T1 (de) 2005-08-15

Family

ID=27047894

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00973636T ATE300302T1 (de) 2000-01-18 2000-10-18 Pharmazeutische zusammensetzung enthaltend einen metabolit von buspirone

Country Status (22)

Country Link
US (1) US6150365A (de)
EP (1) EP1248622B1 (de)
JP (1) JP2003520236A (de)
KR (1) KR20020073176A (de)
CN (1) CN1424911A (de)
AR (1) AR028201A1 (de)
AT (1) ATE300302T1 (de)
AU (1) AU775591B2 (de)
BR (1) BR0016971A (de)
CA (1) CA2406732A1 (de)
CZ (1) CZ20022461A3 (de)
DE (1) DE60021609D1 (de)
HU (1) HUP0204285A3 (de)
IL (1) IL150019A0 (de)
MX (1) MXPA02007003A (de)
NO (1) NO20023425L (de)
NZ (1) NZ520823A (de)
PL (1) PL355966A1 (de)
RU (1) RU2254132C2 (de)
TW (1) TWI226831B (de)
UY (1) UY26440A1 (de)
WO (1) WO2001052853A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137206A1 (en) * 1999-08-05 2005-06-23 Yevich Joseph P. Method for treatment of anxiety and depression
US6150365A (en) * 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
US20030069251A1 (en) * 1999-08-05 2003-04-10 Yevich Joseph P. Antianxiety composition
JP2005502318A (ja) * 2001-03-22 2005-01-27 メルク　エンド　カムパニー　インコーポレーテッド Ｍｃｈ１ｒ欠損マウス
US6593331B2 (en) 2001-04-17 2003-07-15 Laboratories Upsa Method for treatment of pain
EP1408979A4 (de) 2001-07-24 2005-03-23 Bristol Myers Squibb Co R-6-hydroxy-buspiron
EP1417203A4 (de) * 2001-07-24 2005-08-10 Bristol Myers Squibb Co S 6 hydroxy-buspiron
CN1674904A (zh) * 2002-08-12 2005-09-28 布里斯托尔-迈尔斯斯奎布公司 用于羟基氮哌酮类的改进方法
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
WO2004066987A2 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
CN101273046B (zh) * 2005-09-28 2011-05-25 弗·哈夫曼-拉罗切有限公司 作为加压素受体拮抗剂的吲哚-3-基-羰基氮杂螺环衍生物
CA2813648C (en) 2010-10-15 2019-06-25 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
SG11201406690SA (en) 2012-04-18 2014-11-27 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
PT3160464T (pt) 2014-06-26 2018-10-12 Contera Pharma Aps 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
CN109689036A (zh) 2016-07-11 2019-04-26 康特拉医药公司 用于治疗早晨运动不能的脉冲药物输送系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4409223A (en) * 1982-08-06 1983-10-11 Riblet Leslie A Anxiolytic method
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
IL114026A (en) * 1994-06-08 1999-06-20 Lundbeck & Co As H 4-aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzo thiophenemethyl) piperidines tetrahydropyridines or piperazines and pharmaceutical compositions containing them
AU5101798A (en) * 1996-12-04 1998-06-29 Bristol-Myers Squibb Company Method for oral administration of buspirone
US6150365A (en) * 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method

Also Published As

Publication number Publication date
AU775591B2 (en) 2004-08-05
HUP0204285A3 (en) 2004-07-28
BR0016971A (pt) 2002-10-15
DE60021609D1 (de) 2005-09-01
CA2406732A1 (en) 2001-07-26
IL150019A0 (en) 2002-12-01
US6150365A (en) 2000-11-21
AU1213001A (en) 2001-07-31
CN1424911A (zh) 2003-06-18
EP1248622B1 (de) 2005-07-27
EP1248622A4 (de) 2004-02-04
PL355966A1 (en) 2004-05-31
WO2001052853A1 (en) 2001-07-26
RU2254132C2 (ru) 2005-06-20
TWI226831B (en) 2005-01-21
NO20023425L (no) 2002-09-05
AR028201A1 (es) 2003-04-30
MXPA02007003A (es) 2003-01-28
JP2003520236A (ja) 2003-07-02
CZ20022461A3 (cs) 2003-09-17
NZ520823A (en) 2004-05-28
KR20020073176A (ko) 2002-09-19
UY26440A1 (es) 2001-08-27
NO20023425D0 (no) 2002-07-17
HUP0204285A2 (en) 2003-05-28
RU2002118304A (ru) 2004-01-10
EP1248622A1 (de) 2002-10-16

Similar Documents

Publication Publication Date Title
ATE468324T1 (de) Pharmazeutische zusammensetzung
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
ATE395053T1 (de) Pharmazeutische salze von 1-phenyl-3- dimethylamino-propan-verbindungen
ATE404180T1 (de) Geschmacksmaskierte pharmazeutische partikel
ATE449079T1 (de) Pharmazeutische zusammensetzungen beinhaltend kristallsalze von 7-ä4-(4-fluorophenyl)-6- isopropyl-2-
DE60106623D1 (de) Neue pharmazeutische zusammensetzung
ATE334656T1 (de) Flüssige pharmazeutische zusammensetzung
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
NO20030627L (no) Hydrogel-drevet medikament doseringsform
NO20025450L (no) Ny farmasöytisk sammensetning
PT1307457E (pt) Compostos heterociclicos sua preparacao e utilizacao como medicamentos noemadamente como antibacterianos
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
DE60201859D1 (de) Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
DE60111769D1 (de) Flüssige pharmazeutische formulierungen mit verbesserter oraler veträglichkeit
DE60021609D1 (de) Pharmazeutische Zusammensetzung enthaltend einen Metabolit von Buspirone
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
DE60211183D1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
DE60129238D1 (de) Pharmazeutische zusammensetzung
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60136367D1 (de) Pharmazeutische zusammensetzung mit modifiziertem träger
PT1272499E (pt) Composicoes farmaceuticas contendo oligossacaridos e a sua preparacao
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
EP1051141A4 (de) Insulin haltige pharmazeutische zusammensetzungen enthaltend einen amylinagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties